ReviewDrug design, development and therapy2025
Histone Lactylation in Diseases: Regulation by Traditional Chinese Medicine and Therapeutic Implications.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lactylation: a metabolic-epigenetic bridge in diabetic kidney disease and a therapeutic target for TCM.Chinese medicine · 2026Review
- Targeting Lactylation Offers Therapy to Reverse Cell Death Resistance.Drug design, development and therapy · 2025Review
- Lactylation in digestive system tumors: from mechanisms to therapeutic target.Frontiers in oncology · 2025Review
- Decoding protein lactylation in the pathogenesis and progression of gynecological cancer.American journal of cancer research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histone lactylation, as a common post-translational modification (PTM), is crucial in diseases. Aberrant histone lactylation has been linked to disease pathogenesis, thus positioning it as a therapeutic target. This review summarizes the bidirectional relationship between histone lactylation and diseases, emphasizing how Traditional Chinese medicine (TCM) regulates lactate levels to restore histone lactylation homeostasis. Mechanistically, TCM modulates histone lactylation through dual regulation of lactyltransferases and lactate metabolism, thereby influencing disease progression in inflammatory, metabolic, and neoplastic disorders. Notably, TCM is characterized by unique advantages of cost-effectiveness, high efficacy, and minimal adverse effects. For diseases with established drug resistance, TCM offers a promising therapeutic alternative in managing drug-resistant illness by regulating histone lactylation. This review is conducive to understanding the relationship between histone lactylation and disease. TCM effectively treats diseases through the regulation of histone lactylation, thereby highlighting its potential for disease treatment application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.